<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02027818</url>
  </required_header>
  <id_info>
    <org_study_id>BR-TUM-ICG-IV</org_study_id>
    <nct_id>NCT02027818</nct_id>
  </id_info>
  <brief_title>Study of the ICG Distribution in the Margins of Breast Cancer After Tumorectomy</brief_title>
  <official_title>Study of the (Intravenously Injected) Indocyanine Green Distribution in the Margins of Breast Cancer After Tumorectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jules Bordet Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jules Bordet Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will observe if ICG fluorescence correlates with margins of breast tumours after iv&#xD;
      injection of the contrast agent&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the operating room:&#xD;
&#xD;
      ICG 0.25 mg/kg will be given as an iv injection at least 20 minutes before the beginning of&#xD;
      the operation.&#xD;
&#xD;
      The surgeon will remove the tumour (and the axillary lymph nodes) as usual.&#xD;
&#xD;
      Optionally, peroperative &quot;in vivo&quot; imaging of the dissection of the tumour using the PDE&#xD;
      camera will be performed.&#xD;
&#xD;
      In the Laboratory of Pathology:&#xD;
&#xD;
      The &quot;fresh&quot; tumorectomy piece will be processed as usual, and the thick sections for the&#xD;
      evaluation of the margins as well as the tissues samples from each margins will be imaged&#xD;
      using the PDE in comparison with the fluorescence in the mid part of the tumour and the&#xD;
      fluorescent areas will be so delimited (and later analyzed in comparison with standards of&#xD;
      known fluorescence intensity).&#xD;
&#xD;
      After fixation, the tumoral tissues will be thereafter processed &quot;as usual&quot;.&#xD;
&#xD;
      If fluorescent foci are identified at the level of the axillary piece (in case of CALND),&#xD;
      they will be dissected and processed as other lymph nodes. Additionally, metastatic lymph&#xD;
      nodes -if present- will also be controlled for their microscopic fluorescence or not.&#xD;
&#xD;
      Using the near-infrared fluorescence microscope, the slides corresponding to the&#xD;
      macroscopically fluorescent structures will be analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- Evaluation of the ability of NIR imaging to show (fluorescent) the tumoral volumes, the tumoral tissues to be analyzed by the pathologist, especially at the level of the operative margins</measure>
    <time_frame>17 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Analysis of the correlation between (levels of) ICG fluorescence and tumour margins as defined at the microscopic level by the pathologist</measure>
    <time_frame>17 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Indocyanine Green</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>study of the correlation between fluorescence and margins of the tumours after iv injection of Indocyanine Green</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indocyanine Green</intervention_name>
    <description>Observation of the correlation between fluorescence and margins of the tumour after IV injection of ICG</description>
    <arm_group_label>Indocyanine Green</arm_group_label>
    <other_name>ICG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histopathological diagnosis of mammary cancer who are candidate for&#xD;
             tumorectomy, either with SLN selective lymphadenectomy, or with complete axillary node&#xD;
             dissection,&#xD;
&#xD;
          -  Informed consent form signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of mammary cancer established by &quot;gross&quot; biopsy,&#xD;
&#xD;
          -  Age less than18 years old.&#xD;
&#xD;
          -  Inability to give informed consent.&#xD;
&#xD;
          -  History of allergy or hypersensitivity against the investigational product (its active&#xD;
             substance or ingredients), to iodine or to shellfish.&#xD;
&#xD;
          -  Apparent hyperthyroidism, autonomous thyroid adenoma, unifocal, multifocal or&#xD;
             disseminated autonomies of the thyroid gland.&#xD;
&#xD;
          -  Documented coronary disease.&#xD;
&#xD;
          -  Advanced renal impairment (creatinine &gt; 1,5mg/dl).&#xD;
&#xD;
          -  During the 2 weeks before the enrolment, concurrent medication which reduces or&#xD;
             increases the extinction of ICG (i.e. anticonvulsants, haloperidol and Heparin).&#xD;
&#xD;
          -  Pregnancy, breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dani√®le Noterman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jules Bordet Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jules Bordet Institute</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>January 2, 2014</study_first_submitted>
  <study_first_submitted_qc>January 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2014</study_first_posted>
  <last_update_submitted>October 14, 2014</last_update_submitted>
  <last_update_submitted_qc>October 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>margins</keyword>
  <keyword>tumorectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

